Erratum to “First in-human evaluation of [1-13C]pyruvate in D2O for hyperpolarized MRI of the brain: A safety and feasibility study”

Abstract

Kofi Deh, K, Zhang, G, Park, AH, et al. First in-human evaluation of [1-¹³C]pyruvate in D₂O for hyperpolarized MRI of the brain: a safety and feasibility study. Magn Reson Med 2024; 91: 2559–2567.

In the article entitled “First in-human evaluation of [1-¹³C]pyruvate in D₂O for hyperpolarized MRI of the brain: A safety and feasibility study”, the authors stated that five volunteers were imaged; however, Figures 3 and 4 show data from only four subjects. One volunteer's data was omitted from the analysis because of the premature termination of the acquisition due to a loose cable.

The inclusion of the partial data does not change the conclusion of the article. We apologize for not mentioning this in the original manuscript.

Additionally, here, we clarify study details not fully described in the original manuscript. The study was compared between two sites using the same imaging protocol for phantom tests and human studies. Ethics at site 2 was approved by the Sunnybrook Research Ethics Board and by Health Canada as a Clinical Trail Application.¹ The coil setup at site 2 used an 8-rung low-pass birdcage for ¹³C, interchanged with an 8-channel in vivo head coil.¹ SNR differences between two sites were because of the use of different coils, confirmed by phantom studies, which contributed to the failure to detect bicarbonate at site 1, whereas site 2 successfully detected it.¹ T₁ estimates of the pyruvate sample were performed using a multi-nuclear spectroscopy software (GE Healthcare, NY), with a sequence using a 2D spectral-spatial excitation pulse and single-shot spiral readout.

These clarifications do not impact the conclusions of the study, and we apologize for any confusion.